Mark Pruzanski

Chief Executive Officer, Intercept Pharmaceuticals.

Companies

Equillium, Inc.Board member Oct 11, 2018 to now¹
Intercept PharmaceuticalsBoard member Oct 10, 2012 to Nov 13, 2023²
Intercept PharmaceuticalsChief executive officer Oct 10, 2012 to Oct 5, 2020²
Intercept PharmaceuticalsPresident Oct 10, 2012 to Oct 5, 2020²
Intercept PharmaceuticalsOfficer Feb 12, 2016 to Feb 12, 2016³

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Nov 8, 2023U 618,894 shares at $19.00 of Intercept Pharmaceuticals⁴
Nov 30, 2021Shares withheld for tax 3,817 shares at $17.21 of Intercept Pharmaceuticals⁵
Nov 30, 2021Granted 6,138 shares at $17.21 of Intercept Pharmaceuticals⁵
Oct 29, 2021Shares withheld for tax 3,817 shares at $16.86 of Intercept Pharmaceuticals⁶
Oct 29, 2021Granted 6,138 shares at $16.86 of Intercept Pharmaceuticals⁶
Sep 30, 2021Shares withheld for tax 3,816 shares at $14.85 of Intercept Pharmaceuticals⁷
Sep 30, 2021Granted 6,136 shares at $14.85 of Intercept Pharmaceuticals⁷

The numbers on this page point here. Each one links to the record it came from.